Turunen SP, et al. (2019) FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis. Cell Death Differ 30903103

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T177-p - MST1 (human) ▲
Modsite: VAGQLTDtMAkRNtV SwissProt Entrez-Gene Orthologous residues MST1 (human): T177‑p, MST1 iso2 (human): T177‑p, MST1 (mouse): T177‑p, MST1 (rat): T177‑p

T183-p - MST1 (human) ▲

Modsite: DtMAkRNtVIGTPFW SwissProt Entrez-Gene Orthologous residues MST1 (human): T183‑p, MST1 iso2 (human): T183‑p, MST1 (mouse): T183‑p, MST1 (rat): T183‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  breast cancer Relevant cell lines - cell types - tissues:  BT-474 (breast cell), MDA-MB-453 (breast cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE MST1 (human) autophosphorylation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes FGFR4 (human) decrease FGFR4-siRNA increase serum decrease mutation FGFR4 (human) increase MST1 Y433F mutant BLU9931 increase Downstream Regulation Effect of modification (function):  enzymatic activity, induced Effect of modification (process):  apoptosis, induced

S320-p - MST1 (human) ▲
Modsite: DQDDEENsEEDEMDs SwissProt Entrez-Gene Orthologous residues MST1 (human): S320‑p, MST1 iso2 (human): S320‑p, MST1 (mouse): S320‑p, MST1 (rat): S320‑p

S410-p - MST1 (human) ▲
Modsite: EkENQINsFGksVPG SwissProt Entrez-Gene Orthologous residues MST1 (human): S410‑p, MST1 iso2 (human): S410‑p, MST1 (mouse): S410‑p, MST1 (rat): S410‑p Characterization Methods used to characterize site in vivo:  mass spectrometry (in vitro), phospho-antibody

Y433-p - MST1 (human) ▲

Modsite: kIPQDGDyEFLksWt SwissProt Entrez-Gene Orthologous residues MST1 (human): Y433‑p, MST1 iso2 (human): Y433‑p, MST1 (mouse): Y433‑p, MST1 (rat): Y433‑p Characterization Methods used to characterize site in vivo:  mass spectrometry (in vitro), mutation of modification site, phospho-antibody Disease tissue studied:  breast cancer Relevant cell lines - cell types - tissues:  COS (fibroblast), MDA-MB-231 (breast cell), T47D (breast cell) Cellular systems studied:  cell lines Species studied:  green monkey, human Enzymes shown to modify site in vitro:  Type Enzyme KINASE FGFR4 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE FGFR4 (human) phospho-antibody, siRNA inhibition of enzyme, transfection of wild-type enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes siRNA decrease FGFR1-siRNA inhibits Downstream Regulation Effect of modification (function):  enzymatic activity, inhibited, phosphorylation Associated Diseases Diseases Alterations Comments HER2 positive breast cancer decreased